Antikor Takes Aim At Solid Tumors With Antibody-Fragment Conjugates
Executive Summary
Emerging Company Profile: The UK's Antikor Biopharma is advancing antibody fragment-drug conjugates (FDCs) closer to the clinic with plans for its first human study in 2019 or 2020.